News

DENVER, Colo. – If cancer patients are to receive optimal treatment, clinicians must have an accurate histologic classification of the tumor and know its genetic characteristics, said William D. Travis, M.D., attending thoracic pathologist, Department of Pathology, at Memorial Sloan Kettering Cancer Center in New York City. Dr. Travis made his remarks today at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC).

DENVER, Colo. – The publication of the Eighth Edition of the Tumor, Node and Metastasis (TNM) Classification of Lung Cancer will provide physicians around the world access to new data to more precisely stage and treat cases of lung cancer. That data, collected by the International Association for the Study of Lung Cancer (IASLC) Staging and Prognostic Factors Committee and presented at the 16th World Conference on Lung Cancer (WCLC) in Denver on Tuesday, Sept. 8, 2015 at the Colorado Convention Center, will be published in 2016.

DENVER, Colo. — Adding the angiogenesis inhibitor bevacizumab to standard treatment for malignant pleural mesothelioma (MPM) increases life expectancy without severe toxicity, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC). The French multicenter randomized phase 3 trial data was presented by Dr. Arnaud Scherpereel, Head of the Pulmonary and Thoracic Oncology Department and Professor at the University Hospital (CHU) of Lille, France.

DENVER, Colo. — Two Phase III studies with anamorelin found that the medication effectively combats wasting and increases body weight and lean body mass in certain lung cancer patients. Results from the ROMANA 1 and ROMANA 2 Phase III trial of anamorelin were presented today in Denver, Colo. at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC).

DENVER, Colo. — Every hour lost to the cancer drug regulatory process costs 29 life-years lost in the U.S. and 260 life-years worldwide, according to research presented today at 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC). Dr. David Stewart, Head, Division of Medical Oncology, University of Ottawa/The Ottawa Hospital, presented data on how the regulatory process of new therapies slows progress by increasing drug developments costs and by producing speed bumps that delay approval of useful drugs. This process also increases resources required to document that other agents are ineffective.

DENVER, Colo. — The International Association for the Study of Lung Cancer (IASLC) today issued a new statement on Tobacco Control and Smoking Cessation at the 16th World Conference on Lung Cancer (WCLC) in Denver. The statement calls for higher taxes on tobacco products, comprehensive advertising and promotion bans of all tobacco products and product regulation including pack warnings.

Pages